229 related articles for article (PubMed ID: 7620708)
1. Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor.
Telford SE; Smith AI; Lew RA; Perich RB; Madden AC; Evans RG
Br J Pharmacol; 1995 Mar; 114(6):1185-92. PubMed ID: 7620708
[TBL] [Abstract][Full Text] [Related]
2. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.
Tomoda F; Lew RA; Smith AI; Madden AC; Evans RG
Br J Pharmacol; 1996 Sep; 119(2):365-73. PubMed ID: 8886422
[TBL] [Abstract][Full Text] [Related]
3. Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo.
Lew RA; Tomoda F; Evans RG; Lakat L; Boublik JH; Pipolo LA; Smith AI
Br J Pharmacol; 1996 Jul; 118(5):1269-77. PubMed ID: 8818353
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiotensin converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-phenylpropyl-alanyl-alanyl-phenylalanyl-p-aminobenzoate.
Chappell MC; Welches WR; Brosnihan KB; Ferrario CM
Peptides; 1992; 13(5):943-6. PubMed ID: 1336190
[TBL] [Abstract][Full Text] [Related]
5. Effects of a metalloendopeptidase-24.15. Inhibitor on renal hemodynamics and function in rats.
Yang XP; Saitoh S; Scicli AG; Mascha E; Orlowski M; Carretero OA
Hypertension; 1994 Jan; 23(1 Suppl):I235-9. PubMed ID: 8282366
[TBL] [Abstract][Full Text] [Related]
6. Evidence that enzymatic conversion of N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of endopeptidase 24.15, to N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala is necessary for inhibition of angiotensin converting enzyme.
Cardozo C; Orlowski M
Peptides; 1993; 14(6):1259-62. PubMed ID: 8134308
[TBL] [Abstract][Full Text] [Related]
7. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
8. Endopeptidase 24.15 modulates bradykinin-induced contraction in guinea-pig trachea.
Da Silva A; Dhuy J; Waeldelé F; Bertrand C; Landry Y
Eur J Pharmacol; 1992 Feb; 212(1):97-9. PubMed ID: 1372868
[TBL] [Abstract][Full Text] [Related]
9. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.
Lasdun A; Reznik S; Molineaux CJ; Orlowski M
J Pharmacol Exp Ther; 1989 Nov; 251(2):439-47. PubMed ID: 2681686
[TBL] [Abstract][Full Text] [Related]
11. Endopeptidase 3.4.24.11 converts N-1-(R,S)carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a potent inhibitor of angiotensin-converting enzyme.
Williams CH; Yamamoto T; Walsh DM; Allsop D
Biochem J; 1993 Sep; 294 ( Pt 3)(Pt 3):681-4. PubMed ID: 8379924
[TBL] [Abstract][Full Text] [Related]
12. Influence of several peptidase inhibitors on the pro-inflammatory effects of substance P, capsaicin and collagenase.
Damas J; Bourdon V; Liégeois JF; Simmons WH
Naunyn Schmiedebergs Arch Pharmacol; 1996 Nov; 354(5):662-9. PubMed ID: 8938667
[TBL] [Abstract][Full Text] [Related]
13. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiotensin converting enzyme by CV-3317, a non-sulfhydryl compound.
Inada Y; Terashita Z; Imura Y; Tanabe M; Nishikawa K; Kikuchi S
Jpn J Pharmacol; 1986 Sep; 42(1):99-108. PubMed ID: 3025487
[TBL] [Abstract][Full Text] [Related]
16. Correlation between lung and plasma angiotensin converting enzyme and the hypotensive effect of captopril in conscious rabbits.
Chen X; Pitt BR; Moalli R; Gillis CN
J Pharmacol Exp Ther; 1984 Jun; 229(3):649-53. PubMed ID: 6327968
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of captopril on regional haemodynamic responses to angiotensin I and bradykinin in conscious rats.
Gardiner SM; Kemp PA; Bennett T
Br J Pharmacol; 1993 Mar; 108(3):769-75. PubMed ID: 8467363
[TBL] [Abstract][Full Text] [Related]
18. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
19. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
[TBL] [Abstract][Full Text] [Related]
20. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension.
Morrell NW; Morris KG; Stenmark KR
Am J Physiol; 1995 Oct; 269(4 Pt 2):H1186-94. PubMed ID: 7485548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
